Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
In the context of breast cancer, dysregulation of ERK/MAPK pathway can lead to uncontrolled cell growth, increased metastatic potential, and resistance to conventional therapies. At Alfa Cytology, we specialize in unraveling the intricacies of the ERK/MAPK pathway and developing of new ERK/MAPK pathway inhibitor for breast cancer therapy.
The ERK/MAPK pathway is a fundamental signaling cascade that integrates extracellular signals, such as growth factors and cytokines, and transduces them into intracellular responses. In the context of breast cancer, dysregulation of this pathway can lead to the hallmarks of this malignancy, including uncontrolled cell proliferation, evasion of apoptosis, and increased migratory and invasive capabilities.
Fig.1 Schematic overview of the Ras/MAPK signaling pathway. (Giltnane J. M., et al. 2014)
At the core of this signaling network are the Ras, Raf, MEK, and ERK proteins, which form a highly orchestrated cascade of phosphorylation events. Alterations in the activity or expression of these key components can disrupt the delicate balance of cellular processes, ultimately contributing to the initiation and progression of breast cancer.
The ERK/MAPK (extracellular signal-regulated kinase/mitogen-activated protein kinase) signaling pathway is a critical target for the development of novel breast cancer therapies. Several types of ERK/MAPK pathway inhibitors are being explored for the treatment of breast cancer, each with its own unique mechanism of action and potential therapeutic applications.
| NCT number | Target | Therapeutic | Phase |
| NCT02322853 | p38 MAPK | LY2228820 dimesylate | |
| NCT01155453 | MEK | GSK1120212 | |
| NCT06239623 | MAPK Signaling Pathway | JSI-1187 | |
| NCT06287463 | MAPK Pathway | DCC-3084 | |
| NCT06299839 | MEK (1/2) | PAS-004 | |
| NCT04249843 | RAF | BGB-3245 |
Recognizing the pivotal role of the ERK/MAPK pathway in breast cancer, the researchers at Alfa Cytology have dedicated their efforts to the development of targeted inhibitors that can disrupt this critical signaling axis. By selectively targeting key components within the pathway, such as Raf kinases, MEK, and ERK, our team aims to design novel therapeutic strategies that can effectively combat breast cancer.
Raf Kinase Inhibitor Development
MEK Inhibitor Development
ERK Inhibitor Development
At Alfa Cytology, we pride ourselves on our comprehensive suite of preclinical services tailored to the development of innovative ERK/MAPK pathway inhibitors for breast cancer. We are committed to driving the development of transformative E Platform RK/MAPK pathway inhibitors that have the potential to revolutionize the treatment of breast cancer. To learn more about our capabilities in ERK/MAPK pathway inhibitor development for breast cancer or to discuss potential collaborative opportunities, please don't hesitate to contact us.
Reference
